AnodyneWiki

Amphetamine

Speed
Amphetamine
Salts
[]
Amphetamine hemisulfate
Amphetamine hemisulfate
Amphetamine hydrochloride
Amphetamine hydrochloride
Amphetamine adipate
Amphetamine adipate
Amphetamine tartrate
Amphetamine tartrate
Amphetamine phosphate
Amphetamine phosphate
Molecular structure drawn from PubChem coordinates
Physical properties
[]
Molecular mass135.21 g/mol [1]
AppearanceMobile liquid [1]
OdorAmine odor [1]
TasteAcrid, burning taste [1]
Density0.913 at 77 °F (EPA, 1998) - Less dense than water; will float [1]
Melting point-98 °C [1]
Boiling point392 to 397 °F at 760 mmHg (EPA, 1998) [1]
DecompositionWhen heated to decomposition it emits toxic fumes of nitroxides. [1]
SolubilityModerate solubility [1]
Predicted LogP1.8 [1]
Structural Identifiers
[]
Molecular formulaC9H13N
IUPAC name1-phenylpropan-2-amine
SMILESCC(CC1=CC=CC=C1)N
InChIInChI=1S/C9H13N/c1-8(10)7-9-5-3-2-4-6-9/h2-6,8H,7,10H2,1H3
InChIKeyKWTSXDURSIMDCE-UHFFFAOYSA-N
CAS number300-62-9
UNIICK833KGX7E
PubChem CID3007
Pharmacokinetics[]
OnsetImmediate release dosing: 30-45 minutes, Extended release dosing: 1.5-2 hours[3][4]
Elimination half-lifedextroamphetamine: 9-11 hours, levoamphetamine: 11-14 hours, pH-dependent: 7-34 hours[5]
Duration of actionImmediate release dosing: 3-6 hours, Extended release dosing: 8-12 hours
MetabolismCYP2D6, DBH, FMO3
ExcretionPrimarily renal;, pH-dependent range: 1-75%
Routes of administrationMedical: Oral, Recreational: Oral, insufflation, rectal, intramuscular, intravenous
Dependence liabilityPhysical: None, Psychological: Moderate
Addiction liabilityModerate
Toxicity
[]
Mouse:
- oral: 22 mg/kg
- ip: 16 mg/kg
Rat:
- ip: 125 mg/kg
- sc: 39 mg/kg
- Subcutaneous: 180 mg/kg
 [1]
Dosing[]
Insufflated
[]
Light≤ 13.2 mg(518x - 25.4%)
Common13.2 - 20 mg(635x - 31.2%)
Strong20 - 30 mg(449x - 22.0%)
Heavy30 - 44 mg(233x - 11.4%)
Extreme44 mg +(202x - 9.9%)
Intravenous
[]
Light≤ 25 mg(430x - 46.7%)
Common25 - 30 mg(178x - 19.3%)
Strong30 - 35 mg(165x - 17.9%)
Heavy35 - 40 mg(75x - 8.1%)
Extreme40 mg +(73x - 7.9%)
Sublingual
[]
Light≤ 13.9 mg(2x - 40.0%)
Common13.9 - 15 mg(1x - 20.0%)
Strong15 - 37.5 mg(1x - 20.0%)
Heavy37.5 - 45 mg
Extreme45 mg +(1x - 20.0%)
Oral
[]
Light≤ 17 mg(374x - 25.9%)
Common17 - 30 mg(446x - 30.8%)
Strong30 - 50 mg(305x - 21.1%)
Heavy50 - 97 mg(178x - 12.3%)
Extreme97 mg +(143x - 9.9%)
Intrarectal
[]
Light≤ 40.7 mg(19x - 33.9%)
Common40.7 - 70 mg(11x - 19.6%)
Strong70 - 100 mg(15x - 26.8%)
Heavy100 - 162.5 mg(5x - 8.9%)
Extreme162.5 mg +(6x - 10.7%)
Statistically derived dosages via DBI-IGS (archived by anodyne.wiki)
We do not take any responsibility for medical complications or loss of life sustained by following these dosages blindly.

Amphetamine (also known as Amfetamine, dl-Amphetamine, 1-Phenyl-2-aminopropane, Desoxynorephedrine, Norephedrane, Elastonon, Fenopromin, Phenedrine, β-Aminopropylbenzene or Propisamine) is a stimulant substance of the amphetamine class.

Chemistry

Salts []

Amphetamine is typically found in the form of its hemisulfate, hydrochloride, adipate, tartrate and phosphate salts.

 []

Amphetamine is a racemic mixture of the (optical activity ( + / - )).

Stereoisomers from PubChem

Amphetamine matches Lipinski's rule of five.

There are currently 9 reagent-interactions on

ReagentColor changeDescription
Marquisjust orange spots
Meckeno color change
MandelinNeon green / blue
Liebermannorange > red
Robadopepink
Simon'sno blue color change
Ehrlichno color change
Hofmannno color change
Zimmermannno change / faint yellow

Pharmacology

Mechanism of action []

Amphetamine's structure closely resembles catecholamine neurotransmitters, characterized primarily by a long planar conformation, an aromatic ring, and nitrogen in the aryl side chain. Like endogenous catecholamines, amphetamine is actively transported into presynaptic nerve terminals via monoamine reuptake transporters, which require association with two sodium ions and one chloride ion. Because amphetamine acts as a competitive substrate, increased concentrations lead to greater internalization of amphetamine. Once in the presynaptic terminal, amphetamine competes for storage in VMAT2 (Vesicular Monoamine Transporter 2), displacing other monoamines. This action induces the release of neurotransmitters into the synapse through a process known as reverse transport. The d-isomer is approximately fourfold more potent than the $l$-isomer in promoting dopamine release via this mechanism. The mechanism of action is further complemented by the inhibition of both monoamine reuptake and monoamine oxidase (MAO), which act synergistically to significantly elevate monoamine concentrations. Amphetamine does not act as a direct inhibitor but rather as a competitive substrate, classifying it as a weak dopamine reuptake inhibitor, a moderate noradrenaline reuptake inhibitor, and a very weak serotonin reuptake inhibitor. Consequently, the l-isomer exhibits significantly lower potency in this specific action. Amphetamine acts as a weak inhibitor of the mitochondrial-bound enzyme MAO, the catalytic enzyme responsible for degrading excess neurotransmitters. Although this mechanism is often considered minor due to its weak inhibitory nature, it remains a component of amphetamine's overall action. Amphetamine is a modulator of glutamatergic neurotransmission, primarily via its action on the dopamine system. The mass release of dopamine caused by amphetamine subsequently signals to the glutamatergic system, leading to long-lasting changes in synaptic plasticity. Amphetamine's entry into dopamine neurons triggers the endocytosis of the excitatory amino acid transporter EAAT3, reducing glutamate clearance and potentiating excitatory synaptic responses mediated by ionotropic receptors. Chronic exposure also alters receptor composition, such as the downregulation of the NMDA receptor NR2B subunit in the striatum, which is a key molecular change underlying behavioral sensitization to the drug. [1]

Prodrugs of amphetamine: Amfetaminil, Amphecloral, Butylamphetamine, Deprenyl, Desmethyldeprenyl, Dimethylamphetamine, Fenethylline, Fenproporex, Mefenorex, Morforex, ZDCM-04.

Medical side effects []

134 side effects listed on drug labels in (amphetamine).

  • Cardiac death
  • Abdominal pain
  • Stomach ache
  • Gastrointestinal pain
  • Acidosis
  • Aggression
  • Alopecia
  • Anaphylactic shock
  • Angina pectoris
  • Angioedema
  • Decreased appetite
  • Anxiety
  • Arrhythmia
  • Asthenia
  • Fatigue
  • Ataxia
  • Mental disorder
  • Breast disorder
  • Chest pain
  • Coma
  • Infection
  • Confusional state
  • Feeling abnormal
  • Connective tissue disorder
  • Constipation
  • Sudden death
  • Libido decreased
  • Disturbance in sexual arousal
  • Delirium
  • Depression
  • Diarrhoea
  • Polyuria
  • Dizziness
  • Syncope
  • Lightheadedness
  • Dysgeusia
  • Dyskinesia
  • Dysmenorrhoea
  • Dyspepsia
  • Digestion impaired
  • Dyspnoea
  • Toxic epidermal necrolysis
  • Dermatitis
  • Rash
  • Eye disorder
  • Exhaustion
  • Body temperature increased
  • Flushing
  • Gastrointestinal disorder
  • Hallucination
  • Headache
  • Cardiac disorder
  • Hypersensitivity
  • Hypertension
  • Hypotension
  • Irritability
  • Lethargy
  • Mydriasis
  • Myocardial infarction
  • Acute coronary syndrome
  • Nausea
  • Nervous system disorder
  • Nervousness
  • Tension
  • Neuroleptic malignant syndrome
  • Pallor
  • Palpitations
  • Panic reaction
  • Psychotic disorder
  • Psychotic episode
  • Paranoia
  • Rhabdomyolysis
  • Convulsion
  • Shock
  • Sleep terror
  • Speech disorder
  • Erythema multiforme
  • Stevens-Johnson syndrome
  • Cerebrovascular accident
  • Hyperhidrosis
  • Loss of consciousness
  • Tachycardia
  • Tooth disorder
  • Tourette's disorder
  • Tremor
  • Urinary tract infection
  • Urethral disorder
  • Urinary tract disorder
  • Urticaria
  • Allergic urticaria
  • Angiopathy
  • Viral infection
  • Vomiting
  • Weight decreased
  • Dry mouth
  • Chills
  • Agitation
  • Hyperkinesia
  • Mood swings
  • Affect lability
  • Panic attack
  • Drug withdrawal syndrome
  • Growth retardation
  • Haemorrhage intracranial
  • Injury
  • Hyperreflexia
  • Malnutrition
  • Colitis ischaemic
  • Photosensitivity reaction
  • Skin disorder
  • Anhedonia
  • Abdominal pain upper
  • Muscle twitching
  • Increased appetite
  • Dysphoria
  • Choreoathetosis
  • Euphoric mood
  • Disturbance in attention
  • Mental disability
  • Vasculitis cerebral
  • Erectile dysfunction
  • Blood pressure systolic increased
  • Extrasystoles
  • Hyperpyrexia
  • Psychomotor retardation
  • Blood pressure increased
  • Visual impairment
  • Drug dependence
  • Compulsions
  • Tic
  • Cardiomyopathy
  • Hypersomnia
  • Insomnia
  • Somnolence

Indications

  • Appetite absent
  • Attention deficit disorder
  • Attention deficit/hyperactivity disorder
  • Distractibility
  • Electroencephalogram abnormal
  • Forgetfulness
  • Hyperkinesia
  • Learning disability
  • Mental disorder
  • Mood swings
  • Narcolepsy
  • Psychotic disorder

Subjective effects []

0xea / Amphetamine []
Routes:
  • Oral (10 - 50mg)
    Onset: 20 - 35 m
    Duration: 4 - 6 h
  • Insufflated (30 - 60mg)
  • Intrarectal (30 - 90mg)
  • Subcutaneous
    Onset: 25 m
    Duration: 3 - 5 h
  • Intramuscular (10 - 35mg)
  • Intravenous (15 - 50mg)
    Onset: 1 m
    Duration: 3 - 4 h
  • Inhaled
  • Vaporized (5mg)
  • Sublingual (5mg)
Classes:Forms:
  • Sulfate
  • Hydrochloride
Source:
  • Amphetamine Sulfate: DNM Germany
  • Speed paste: Goerlitzer park
  • Speed paste: Drug taxi
  • Speed: Warschauer
Indication:Effects:After Effects:Tolerance:
  • builds steadily over the span of weeks to months
  • sustained use leads to a point where the drugs positive effects are still reachable but at dosages between 50-100mg intravenously and oftentimes only 15-30 minutes at a time.
Odor:
  • freebase smells strongly of rotten fish
  • pristine sulfate is practically odorless
Notes:
a1ko / Amphetamine []
Routes:
  • Insufflated
  • Oral
  • Intravenous
alina / Amphetamine []
Routes:
  • Insufflated (10.0mg)
bonzi / Amphetamine []
emily / Amphetamine []
Routes:
  • Insufflated (9 - 51mg)
  • Oral (10 - 20mg)
magnus / Amphetamine []
Routes:
  • Oral
  • Insufflation
Forms:
  • Sulfate
Effects:
Mere / Amphetamine []
michalina / Amphetamine []
Forms:
  • Bmk
Effects:
  • stimulation
Notes:
  • none of euphoria has been present, pure stimulation
nervewing / Amphetamine []
ninerik / Amphetamine []
Classes:Source:
  • DNM: Speed
Effects:Notes:
  • I will not consume any more amphetamine. I will not consume any more amphetamine. I will not consume any more amphetamine. Okay just one more time :P
Pilz / Amphetamine []
Routes:
  • Oral (3 - 20mg)
  • Insufflated (8 - 46mg)
Forms:
  • Sulfate
Source:
  • Amphetamine: DNM Germany
Indication:Effects:Notes:
  • Consumed close to daliy since 11-2025, helps against ADHD
vivi / Amphetamine []
Routes:
  • Oral (9 - 25mg)
  • Insufflated (6 - 7.5mg)
x86pup / Amphetamine []
Routes:
  • Oral

Experience reports

Erowid

There are currently 30 experience reports involving amphetamine on : []

Reddit

There are currently 50 trip reports involving amphetamine on : []

 []

  • Australia: Amphetamine is a Schedule 8.
  • Brazil: Amphetamine is a A3.
  • Canada: Amphetamine is a Schedule I.
  • Germany: Amphetamine is a Anlage III under the "Betäubungsmittelgesetz (BtMG)".
  • New Zealand: Amphetamine is a Class B.
  • United Kingdom: Amphetamine is a Class B under the "Misuse of Drugs Act 1971".
  • United States: Amphetamine is a Schedule II under the "Controlled Substances Act".[6]
  • United Nations: Amphetamine is a Psychotropic Schedule II.
  • Other: Amphetamine is a SE: Förteckning II.[7]

See also []

External links []

References []

  1. National Center for Biotechnology Information. PubChem Compound Summary for CID 3007, Amphetamine. Accessed November 20, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/3007
  2. U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Amphetamine. UNII: CK833KGX7E. Global Substance Registration System. Accessed November 20, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/CK833KGX7E
  3. Millichap JG. Attention Deficit Hyperactivity Disorder Handbook: A Physician's Guide to ADHD. Springer. 2010.
  4. Brams M, Mao AR, Doyle RL. Onset of efficacy of long-acting psychostimulants in pediatric attention-deficit/hyperactivity disorder. Postgraduate Medicine. September 2008; 120(3):69–88. PMID 18824827. https://doi.org/10.3810/pgm.2008.09.1909
  5. Adderall- dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate, and amphetamine sulfate tablet. DailyMed. 8 November 2019. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f22635fe-821d-4cde-aa12-419f8b53db81
  6. Ingersoll J. Amphetamine, Methamphetamine, and Optical Isomers. Federal Register. 7 July 1971. https://archives.federalregister.gov/issue_slice/1971/7/7/12730-12734.pdf
  7. Läkemedelsverkets föreskrifter (LVFS 2011:10) om förteckningar över narkotika. Läkemedelsverket. https://www.lakemedelsverket.se/globalassets/dokument/lagar-och-regler/lvfs/lvfs-2011-10-konsoliderad.pdf

Data sources []

SourceStatusUpdated (UTC)
dosingok2026-11-20 03:08:03
drugsprook2026-11-20 03:07:59
erowidok2026-11-20 03:08:02
gsrsok2026-11-20 03:08:03
hmdbmissing (hmdb.ca refused automated access to HMDB0014328)2026-11-20 03:07:59
keggok2026-11-20 03:08:00
pubchemok2026-11-20 03:07:57
redditok2026-11-20 03:07:59
siderok2026-11-20 03:07:59
structureok2026-11-20 03:07:59
wikipediaok2026-11-20 03:07:59